Todd C. Brady - 30 Mar 2022 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Role
President and CEO, Director
Signature
/s/ Todd C. Brady
Issuer symbol
ALDX
Transactions as of
30 Mar 2022
Transactions value $
$0
Form type
4
Filing time
01 Apr 2022, 19:44:04 UTC
Previous filing
07 Jun 2021
Next filing
28 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALDX Common Stock Award $0 +250K +26.35% $0.00 1.2M 30 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALDX Employee Stock Option (Right to Buy) Award $0 +250K $0.00 250K 30 Mar 2022 Common Stock 250K $4.52 Direct F2
transaction ALDX Bonus Units Award $0 +208K $0.00 208K 30 Mar 2022 Common Stock 208K $4.52 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
F2 The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022.
F3 The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52.